Last reviewed · How we verify

Tukysa (tucatinib)

Seagen · FDA-approved active Quality 59/100

Tukysa works by blocking the ERBB2/ERBB3 receptors, which are involved in the growth and spread of cancer cells.

Tukysa (tucatinib) is a small molecule kinase inhibitor developed by SEATTLE GENETICS and currently owned by Seagen. It targets the ERBB2/ERBB3 receptors, which are involved in the growth and spread of cancer cells. Tukysa is FDA-approved for the treatment of metastatic human epidermal growth factor 2 positive carcinoma of the breast. It is a patented medication with no generic manufacturers available. Key safety considerations include its potential to cause liver damage and interactions with other medications.

At a glance

Generic nametucatinib
SponsorSeagen
Drug classKinase Inhibitor [EPC]
TargetERBB2/ERBB3
Therapeutic areaOncology
PhaseFDA-approved
First approval2020
Annual revenue463

Mechanism of action

Tucatinib is tyrosine kinase inhibitor of HER2. In vitro, tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells. In vivo, tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone.

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: